

1

treating or preventing autoimmune or inflammatory disorders (e.g. AIDS, allergy, asthma, cancer, etc.).

energy, anemia or anemias), multiple sclerosis, osteoporosis, cancer or hepatitis.

CC vasotropic; cerebroprotective; nootropic; neuroprotective; antibacterial;
 CC vincetide; fungicide; ophthalmologic; and vulnerary. The secreted
 CC proteins, polypeptides and agonists may be useful in
 CC treating, preventing and/or diagnosing diseases and disorders such as
 CC autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
 CC disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
 CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
 CC angioneitis, nervous system disorders e.g. Alzheimer's disease,
 CC infections caused by bacteria, viruses and fungi and ocular disorders
 CC e.g. corneal infection. The polypeptides can also be used to aid wound
 CC healing and epithelial cell proliferation, to prevent skin aging due to
 CC sunburn, to maintain organs before transplantation, for supporting cell
 CC culture of primary tissues, to regenerate tissues and in chemotaxis. The
 CC polypeptides can also be used as a food additive or preservative to
 CC increase or decrease storage capabilities, fat content, lipid, protein,
 CC carbohydrate, vitamins, minerals, cofactors and other nutritional
 CC components. Oligonucleotides AAC95453 - AAC95461 and peptide AAB51928 are
 CC used in the isolation and characterization of the proteins and
 CC polynucleotides of the invention

SQ Sequence 1332 BP; 326 A; 319 C; 329 G; 358 T; 0 U; 0 Other;

Query Match 98.5%; Score 818.4; DB 3; Length 1332;

Best Local Similarity 99.8%; Pred. No. 2.2e-222;

Matches 830; Conservative 0; Mismatches 1; Indels 1; Gaps 1;

1 CGTCTATCTGACAGTGGCTACTTCTCACT-GGCAGAAAGAGCCACATCTGCTTCTCTAG 59
 235 GGTCTTATCTGACAGTGGCTACTTCTCACTGGCAGAAAGAGCCACATCTGCTTCTCTAG 294
 60 GCGCTTGGGAGAAAGCAATGCGTGTGTCTTCTCTGATTTGGGCCCGAGGCTGAGGC 119
 295 GCGCTTGGGAGAAAGCAATGCGTGTGTCTTCTCTGATTTGGGCCCGAGGCTGAGGC 354
 120 AGGCTCCCTGCGCTCAGAAATGATGACAGGCAAAATGAAACACGCGGAAATTTCTG 179
 355 AGGCTCCCTGCGCTCAGAAATGATGACAGGCAAAATGAAACACGCGGAAATTTCTG 414
 180 CAGAAAGAGTGGCTTATCATCTTACATCTTCTCTGACACGAGCAAGTGA 239
 415 CAGAAAGAGTGGCTTATCATCTTACATCTTCTCTGACACGAGCAAGTGA 474
 240 CCGAGGTCACTGGAGACGACGACGCTTGGCCATTGTGATGCTGACTTGGGGT 299
 475 CCGAGGTCACTGGAGACGACGACGCTTGGCCATTGTGATGCTGACTTGGGGT 534
 300 GGCACATCTCCCATCTTCAAGGATGAGTGGCCCGAGGCTGGGCTTCAACC 359
 535 GGCACATCTCCCATCTTCAAGGATGAGTGGCCCGAGGCTGGGCTTCAACC 594
 360 TCCAGTGTGACCGTGAACGATACAGGGAGTACTTCTGATCTATCACTTACCCCTG 419
 595 TCCAGTGTGACCGTGAACGATACAGGGAGTACTTCTGATCTATCACTTACCCCTG 654
 420 ATGGAGCTACACTGGAGAAATCTTCTGAGTCTTGAAGAGTCAAGTGGCTGAGACG 479
 655 ATGGAGCTACACTGGAGAAATCTTCTGAGTCTTGAAGAGTCAAGTGGCTGAGACG 714
 480 GTGCGAGTTCAGATTCATTGCTTGGAGCAAGCGCGGACGCTGTGTGATCTGCA 539
 715 GTGCGAGTTCAGATTCATTGCTTGGAGCAAGCGCGGACGCTGTGTGATCTGCA 774
 540 CAGCAGTCACTGTGTGTGCTGCTTGAAGTGAAGAAAGCCCTCAGATCACTTCTG 599
 775 CAGCAGTCACTGTGTGTGCTGCTTGAAGTGAAGAAAGCCCTCAGATCACTTCTG 834
 600 TGAAGGTGACCTTCAAGAAATCAGCTGACAGAGAAATGAGCCCAAGTCTCTCT 659
 835 TGAAGGTGACCTTCAAGAAATCAGCTGACAGAGAAATGAGCCCAAGTCTCTCT 894
 660 CACCCCAAGAGCTGTGTCTGACAGAGAGTGAACCTGCTGGGCTGTGTGAGAGAGC 719
 895 CACCCCAAGAGCTGTGTCTGACAGAGAGTGAACCTGCTGGGCTGTGTGAGAGAGC 954

QY 720 GGGAGAGACCTGTGCGGAGCTGACATCTTCAATGCTCTGATGATACAGAAAGCTGG 779
 DB 955 GGGAGAGACCTGTGCGGAGCTGACATCTTCAATGCTCTGATGATACAGAAAGCTGG 1014
 QY 780 GTAACTGACCTTCTTCAAGAGACTGGTTGCAACCAAGGCAATCTTCTG 831
 DB 1015 GTAACTGACCTTCTTCAAGAGACTGGTTGCAACCAAGGCAATCTTCTG 1066

RESULT 4

ADL91491 ADL91491 standard; cDNA; 1332 BP.

AC ADL91491;

DT 17-JUN-2004 (first entry)

DE Human immune-related polypeptide PRO52254-encoding cDNA, SEQ ID NO:6.

XX Human; PRO; activated T cell; immune-related; drug screening; detection;
 KW stimulation; immune response; stimulation; diagnosis; immune disorder;
 KW systemic lupus erythematosus; rheumatoid arthritis; osteoarthritis;
 KW juvenile chronic arthritis; spondyloarthritis; systemic sclerosis;
 KW idiopathic inflammatory myopathy; Sjogren's syndrome;
 KW systemic vasculitis; sarcoidosis; autoimmune haemolytic anaemia;
 KW autoimmune thrombocytopenia; thyroiditis; diabetes mellitus;
 KW immune-mediated renal disease; demyelinating disease;
 KW idiopathic demyelinating polyneuropathy; Guillain-Barre syndrome;
 KW chronic inflammatory demyelinating polyneuropathy; hepatobiliary disease;
 KW chronic active hepatitis; primary biliary cirrhosis;
 KW granulomatous hepatitis; sclerosing cholangitis;
 KW inflammatory bowel disease; gluten-sensitive enteropathy;
 KW Whipple's disease; autoimmune skin disease; immune-mediated skin disease;
 KW bullous skin disease; erythema multiforme; contact dermatitis; psoriasis;
 KW allergic disease; asthma; allergic rhinitis; atopic dermatitis;
 KW food hypersensitivity; urticaria; eosinophilic pneumonia;
 KW idiopathic pulmonary fibrosis; hypersensitivity pneumonitis;
 KW transplantation associated disease; graft rejection;
 KW graft-versus-host disease; immunosuppressive; dermatological;
 KW hepatotropic; nephrotoxic; antidiabetic; antihypertensive; antiparasitic;
 KW antiallergic; antianaemic; antiarteriosclerotic; antiarthritic;
 KW neuroprotective; respiratory; antiinflammatory; gene therapy; gene; ss.
 OS Homo sapiens.
 XX
 PN W02004024072-A2.
 PD 25-MAR-2004.
 XX
 PF 10-SEP-2003; 2003WO-US028317.
 PR 11-SEP-2002; 2002US-0410340P.
 XX
 PA (SETH) GENENTECH INC.
 PI Bodary SC, Clark W, Hunte B, Jackman JK, Schoenfeld JR;
 PI Williams PM, Wood WT, Wu TD;
 XX
 DR WPI; 2004-329384/30.
 DR P-PSDB; ADL91492.
 XX
 PT New PRO nucleic acid, useful for preparing a composition for diagnosing
 PT or treating an immune related disorder, e.g., systemic lupus
 PT erythematosus in a mammal.
 XX
 PS Claim 2; SEQ ID NO 6; 199p; English.
 XX
 CC The invention relates to isolated human immune-related polypeptides
 CC (designated PRO) and nucleic acids (ADL91486-ADL91587). The PRO
 CC polypeptides are overexpressed in CD4+ T cells activated by anti-CD3/ICAM
 CC -1 or anti-CD3/anti-CD28 antibodies compared with resting T cells and are
 CC useful as diagnostic markers and therapeutic targets for immune

QY 61 QODQLAICNADLGMHISPSFKDRAVAPGRLGLTQSLTVNDTGRYFCIYHYTPDGTYYG 120
DB 61 QODQLAICNADLGMHISPSFKDRAVAPGRLGLTQSLTVNDTGRYFCIYHYTPDGTYYG 120
QY 121 RIFLEVLSSVAHEGARFQIPLLGMAATLVITCAVTVVVALTRKKALRIHSVGDLR 180
DB 121 RIFLEVLSSVAHEGARFQIPLLGMAATLVITCAVTVVVALTRKKALRIHSVGDLR 180
QY 181 RKSAGQEMSPSPSPSCVQAEAPAGLCEBQGBDCAELHDYFNVLSTYSLGNCSPF 240
DB 181 RKSAGQEMSPSPSPSCVQAEAPAGLCEBQGBDCAELHDYFNVLSTYSLGNCSPF 240
QY 241 TETG 244
DB 241 TETG 244

RESULT 3
ADP76825
ID ADP76825 standard; protein; 257 AA.
AC ADP76825;
DT 26-FEB-2004 (first entry)
DB Novel human secreted and transmembrane protein Seqid 500.
DE human; PRO: membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neurotrophic; hormone; cell receptor;
KW receptor-ligand interaction; cytoskeletal; chondrocyte; tumour.
XX Homo sapiens.
OS
XX WO2003072035-A2.
PD 04-SRP-2003.
XX 21-FEB-2003; 2003WO-US005241.
PF 22-FEB-2002; 2002US-0359461P.
PR (GETH) GENENTECH INC.
PA Bodary SC, Clark H, Hunte B, Jackman JK, Schoenfeld JR;
PI Williams PM, Wood WI, Wu TD;
XX WPI; 2003-721702/68.
DR N-PSDB; ADP76824.
XX
PT New PRO polypeptides, useful for diagnosing and treating an immune
PT related disorder, e.g. systemic lupus erythematosus, rheumatoid
PT arthritis, osteoarthritis, juvenile chronic arthritis, thyroiditis or
PT diabetes mellitus.
XX
PS Claim 10; SEQ ID NO 500; 918pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the

CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is the amino acid sequence of a human PRO protein of the
CC invention.
XX
SQ Sequence 257 AA;
Query Match 100.0%; Score 1286; DB 7; Length 257;
Best Local Similarity 100.0%; Pred. No. 1,2e-112;
Matches 244; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MEMCILLIWAQGLRQAPLPSGMMTGTITFTGNISARKGSIILQCHLSTTAQTVQVNE 60
DB 14 MEMCILLIWAQGLRQAPLPSGMMTGTITFTGNISARKGSIILQCHLSTTAQTVQVNE 73
QY 61 QODQLAICNADLGMHISPSFKDRAVAPGRLGLTQSLTVNDTGRYFCIYHYTPDGTYYG 120
DB 74 QODQLAICNADLGMHISPSFKDRAVAPGRLGLTQSLTVNDTGRYFCIYHYTPDGTYYG 133
QY 121 RIFLEVLSSVAHEGARFQIPLLGMAATLVITCAVTVVVALTRKKALRIHSVGDLR 180
DB 121 RIFLEVLSSVAHEGARFQIPLLGMAATLVITCAVTVVVALTRKKALRIHSVGDLR 180
QY 181 RKSAGQEMSPSPSPSCVQAEAPAGLCEBQGBDCAELHDYFNVLSTYSLGNCSPF 240
DB 181 RKSAGQEMSPSPSPSCVQAEAPAGLCEBQGBDCAELHDYFNVLSTYSLGNCSPF 253
QY 241 TETG 244
DB 254 TETG 257

RESULT 4
ADA21139
ID ADA21139 standard; protein; 311 AA.
XX
AC ADA21139;
DT 20-NOV-2003 (first entry)
XX
DE Human secreted protein SECP-44 SEQ ID NO:44.
XX
KW human, secreted protein; SECP; anti-HIV; anti-allergic; anti-inflammatory;
KW anti-nausea; antiparkinsonian; noctropic; anticonvulsant;
KW antiarteriosclerotic; antiasthmatic; immunosuppressive; antithyroid;
KW cytoskeletal; hepatotropic; dermatological; antidiabetic; nephrotropic;
KW antigout; thyromimetic; neuroprotective; osteopathic; antiarthritic;
KW antiparasitic; antihelminthic; antipsoriatic; uropathic;
KW ophtalmological; antirheumatic; haemostatic; antidiabetic; vitruclide;
KW protocoarctide; fungicide; gene therapy; cell proliferative disorder;
KW arteriosclerosis; atherosclerosis; cirrhosis; hepatitis;
KW paroxysmal nocturnal haemoglobinuria; polycythaemia vera; porriasis;
KW primary thrombocytopaenia; cancer; developmental disorder;
KW renal tubular acidosis; anaemia; mental retardation;
KW neurological disorder; Alzheimer's disease; Parkinson's disease;
KW epilepsy; autoimmune disorder; inflammatory disorder; AIDS; allergy;
KW asthma; autoimmune thyroiditis; contact dermatitis; Crohn's disease;
KW diabetes mellitus; glomerulonephritis; Goodpasture's syndrome; gout;
KW Graves' disease; Hashimoto's thyroiditis; irritable bowel syndrome;
KW multiple sclerosis; osteoarthritis; osteoporosis; pancreatitis;
KW Reiter's syndrome; rheumatoid arthritis; Sjogren's syndrome; uveitis;
KW infection.
XX
OS Homo sapiens.
XX
XX WO2003068943-A2.
PN 21-AUG-2003.
XX
PD 21-AUG-2003.
XX
PF 13-FEB-2003; 2003WO-US004712.
XX

PR 13-FEB-2002; 2002US-0357002P.
PR 06-MAR-2002; 2002US-0362439P.
PR 19-MAR-2002; 2002US-0366041P.

(INCY-) INCYTE GENOMICS INC.

PI Leht-Mason PM, Kable AB, Elliott VS, Margulis JP, Baughn MR;
PI Chavala NK, Tran UK, Jin P, Tang YT, Zeharjadian Y, Svarnakar A;
PI Hafalia AD, Cocks BG, Warren BA, Emerling BM, Pearson CJ, Chien D;
PI Peterson DP, Fu CK, Yue H, Jackson AA, Jiang X, Hawkins PR, Lai PG;
PI Khare R, Lee S, Lee ST, Richardson TW, Chang H;

XX WPI, 2003-689669/65.

DR N-PSDB; ADA21190.

XX New human secreted proteins and polynucleotides, useful for diagnosing,
PT treating or preventing autoimmune or inflammatory disorders (e.g. AIDS,
PT allergy, asthma or anemia), multiple sclerosis, osteoporosis, cancer or
PT hepatitis.

PS Claim 1; Page 245-246; 295pp; English.

XX The present sequence represents a human secreted protein (I) designated
CC SECP-44. (I) have anti-HIV, anti-allergic, anti-inflammatory, anti-nausea,
CC antiparkinsonian, nootropic, anticonvulsant, antiarteriosclerotic,
CC antiaspartic, immunosuppressive, antihypertensive, hepatotropic,
CC dematological, antidiabetic, nephrotropic, angiotensin, thymomimetic,
CC neuroprotective, osteoparathic, antiaortic, antiparasitic,
CC antihelminthic, antiparasitic, uropathic, ophthalmological,
CC antitumoral, hemostatic, antibacterial, virucide, protozoacide and
CC fungicide activities, and can be used in gene therapy. The human secreted
CC proteins (SECP), polynucleotides, agonists and antagonists of the present
CC invention are useful for diagnosing, treating or preventing disorders
CC associated with aberrant expression of SECP, particularly cell
CC proliferative disorders (e.g. arteriosclerosis, atherosclerosis,
CC cirrhosis, hepatitis, paroxysmal nocturnal haemoglobinuria, polycythaemia
CC vera, psoriasis, primary thrombocytopenia or cancer), developmental
CC disorders (e.g. renal tubular acidosis, anaemia or mental retardation),
CC neurological disorders (e.g. Alzheimer's disease, Parkinson's disease or
CC epilepsy), autoimmune/inflammatory disorders (e.g. AIDS, allergies,
CC asthma, autoimmune thyroiditis, contact dermatitis, Crohn's disease,
CC diabetes mellitus, glomerulonephritis, Goodpasture's syndrome, gout,
CC Graves' disease, Hashimoto's thyroiditis, irritable bowel syndrome,
CC multiple sclerosis, osteoarthritis, osteoporosis, pancreatitis, Reiter's
CC syndrome, rheumatoid arthritis, Sjogren's syndrome, uveitis), or viral,
CC bacterial, fungal, parasitic, protozoan or helminthic infections. The
CC SECP and polynucleotides are also useful in assessing the effects of
CC exogenous compounds on the expression of nucleic acids secreted proteins.
CC The polynucleotides encoding SECP are useful for creating transgenic
CC animals to model human disease.

XX Sequence 311 AA;

Query Match 100.0%; Score 1286; DB 6; Length 311;
Best Local Similarity 100.0%; Pred. No. 1.6e-112;

Matches 244; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 1 MRCCLLIIWAQGLRQAPLASGMMGTITETTNISAEKGSIILOCHLSSTTAQVYVMB 60
QY |||||
DB 68 MRCCLLIIWAQGLRQAPLASGMMGTITETTNISAEKGSIILOCHLSSTTAQVYVMB 127
QY |||||
DB 61 OODOLLAICNADLGMHISPSFDRVAPRGGLTLOSLTVNDTGEYFCIYHTYPPGTYG 120
QY |||||
DB 128 OODOLLAICNADLGMHISPSFDRVAPRGGLTLOSLTVNDTGEYFCIYHTYPPGTYG 187
QY |||||
DB 121 RIFLEVLSSVAHGARGQIPLGMAATLVITCTAVIVVVALTRKKALRIHSVGDRL 180
QY |||||
DB 188 RIFLEVLSSVAHGARGQIPLGMAATLVITCTAVIVVVALTRKKALRIHSVGDRL 247
QY |||||
DB 181 RKSAGQEWSPSPGSCVQABAPAGLCSRGEGDCAELHDYFNTLSYSLGNCSPF 240
QY |||||
DB 248 RKSAGQEWSPSPGSCVQABAPAGLCSRGEGDCAELHDYFNTLSYSLGNCSPF 307

QY 241 TETG 244
DB 308 TETG 311

RESULT 5
ADM05498
ID ADM05498 standard; protein; 244 AA.

XX ADM05498;

XX 20-MAY-2004 (first entry)

XX Human protein of the invention SEQ ID NO:4183.

XX human; gene therapy; diagnostic marker; pharmaceutical.

XX Homo sapiens.

XX EP1347046-A1.

XX 24-SEP-2003.

XX 12-APR-2002; 2002EP-00008400.

XX 22-MAR-2002; 2002JP-00137785.

XX (RMS-) RMS ASSOC BIOTECHNOLOGY.

XX Isogai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;
PI Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;
PI Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;

XX WPI, 2003-723558/69.

XX N-PSDB; ADM03055.

XX New polynucleotides and polypeptides are useful in gene therapy, for
PT developing a diagnostic marker or medicines for regulating their
PT expression and activity, or as a target of gene therapy.

XX Claim 1; SEQ ID NO 4183; 305pp; English.

XX The invention relates to a novel human polynucleotide and the encoded
CC polypeptide. A polynucleotide of the invention ADM06202-ADM06773 is useful
CC as a primer for synthesizing the polynucleotide or as a probe for
CC detecting the polynucleotide. The polynucleotides ADM0316-ADM03758 are
CC useful in gene therapy, for developing a diagnostic marker or medicines
CC for regulating their expression and activity, or as a target of gene
CC therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides
CC are useful as pharmaceutical agents. The present sequence represents a
CC protein sequence of the invention.

XX Sequence 244 AA;

Query Match 99.6%; Score 1281; DB 7; Length 244;
Best Local Similarity 99.6%; Pred. No. 3.4e-112;

Matches 243; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MRCCLLIIWAQGLRQAPLASGMMGTITETTNISAEKGSIILOCHLSSTTAQVYVMB 60
DB 1 MRCCLLIIWAQGLRQAPLASGMMGTITETTNISAEKGSIILOCHLSSTTAQVYVMB 60
QY |||||
DB 61 OODOLLAICNADLGMHISPSFDRVAPRGGLTLOSLTVNDTGEYFCIYHTYPPGTYG 120
QY |||||
DB 61 OODOLLAICNADLGMHISPSFDRVAPRGGLTLOSLTVNDTGEYFCIYHTYPPGTYG 120
QY |||||
DB 121 RIFLEVLSSVAHGARGQIPLGMAATLVITCTAVIVVVALTRKKALRIHSVGDRL 180
QY |||||
DB 121 RIFLEVLSSVAHGARGQIPLGMAATLVITCTAVIVVVALTRKKALRIHSVGDRL 180
QY |||||
DB 181 RKSAGQEWSPSPGSCVQABAPAGLCSRGEGDCAELHDYFNTLSYSLGNCSPF 240
QY |||||